- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session3/6/17 8:30 am EST
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that eight abstracts have been accepted for presentation at the American College of Cardiology (ACC) 66th Annual Scientific Session, taking place March 17-19 in Washington, D.C. In addition to post-hoc analyses from the pivotal Phase 3 ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation) trial, the Bristol-more...
- Post-hoc Analyses from the ARISTOTLE Trial Featured in Late-Breaker and Poster Sessions
- Real-World Data Analyses Include Database Reviews of U.S. Medicare Patient Population
2/28/17 6:53 pm ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the pricing of a debt offering consisting of four tranches of notes: €1,250,000,000 aggregate principal amount of floating rate notes due 2019 €1,000,000,000 aggregate principal amount of 0.000% notes due 2020 €1,000,000,000 aggregate principal amount of 0.250% notes due 2022 €750,000,000 aggregate principal amount of 1.000% notes due 2027 Interest on themore...
2/28/17 10:00 am ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by John Young, Group President, Pfizer Essential Health, at the Cowen and Company 37th Annual Healthcare Conference on Tuesday, March 7, 2017 at 11:20 a.m. Eastern Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Cowen and Company 37th Annual Healthcare Conference” link inmore...
2/24/17 1:09 pm ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the pricing of $1,065,000,000 aggregate principal amount of 4.20% notes due 2047. This offering is expected to be sold to professional institutional investors in Taiwan, with application to be made to list the notes on the Taipei Exchange. Pfizer intends to use the net offering proceeds for general corporate purposes, including to repay a portion of its outstanding commercial papermore...
2/23/17 4:15 pm ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the election of Ronald E. Blaylock to its Board of Directors, effective immediately. Mr. Blaylock was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board. Mr. Blaylock, 57, is the Founder, Managing Partner of GenNx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market, since 2006.more...
Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration2/21/17 8:00 am EST
Application Requests Approval for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in AdultsNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that a Biologics License Application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Inotuzumab ozogamicin received Breakthrough Therapy designation frommore...
New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a2/17/17 12:00 pm EST
Pfizer in partnership with Celltrion Healthcare presents new data for INFLECTRA in Crohn’s diseaseNEW YORK--(BUSINESS WIRE)--Data announced jointly today by Pfizer Inc. (NYSE:PFE) and Celltrion Healthcare, at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO), showed that for patients with moderate-to-severe Crohn’s disease (CD), treatment with INFLECTRA (infliximab CT-P13) has similar efficacy and safety to treatment with REMICADE (infliximab).1 The randomized 54 week clinical trial (RCT)2 in 214 patients met its primary end pointmore...
Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab)2/16/17 8:00 am ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA). ORAL Strategy is the first trial to compare a JAK inhibitor as monotherapy or in combination with methotrexate (MTX) versus adalimumab (Humira) plus MTX in MTX inadequate responders using ACR50 at Month 6 as the primary endpoint.more...
Relationship Expert Teams Up with Pfizer to Address Intimacy and Relationship Issues for People Living with Chronic Diseases2/9/17 8:30 am EST
Logan Levkoff, Ph.D., addresses tough topics for those living with rheumatoid arthritis on Arthritis.comNEW YORK--(BUSINESS WIRE)--Nationally-recognized relationship expert and author, Logan Levkoff, Ph.D., has partnered with Pfizer Inc. (NYSE:PFE) to fill a void in information available to people living with chronic diseases: relationship advice. Levkoff will address the topics of relationships and intimacy for those living with a chronic condition, like rheumatoid arthritis (RA), on the newly re-launched Arthritis.com site. The website is a place where people living withmore...
1/31/17 6:45 am EST
PROVIDES 2017 FINANCIAL GUIDANCE
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2016 and provided 2017 financial guidance. Pfizer manages its commercial operations through two distinct businesses: Pfizer Innovative Health (IH)(3) (formerly the Innovative Products business) and Pfizer Essential Health (EH)(3)(4) (formerly the Established Products business). Financial results for each of these businesses are presented in the Operatingmore...
- Full-Year 2016 Revenues of $52.8 Billion, Reflecting 11% Operational Growth; Full-Year 2016 Revenues for Pfizer Standalone (Excluding Legacy Hospira and Legacy Medivation) of $48.1 Billion, Reflecting 5% Operational Growth
- Fourth-Quarter 2016 Revenues of $13.6 Billion, Reflecting 1% Operational Decline, Unfavorably Impacted by Four Fewer U.S. Selling Days and Three Fewer International Selling Days Compared to the Prior-Year Quarter; Fourth-Quarter 2016 Pfizer Standalone Revenues of $12.3 Billion, Reflecting 2% Operational Decline
- Full-Year 2016 Reported Diluted EPS(1) of $1.17, Adjusted Diluted EPS(2) of $2.40; Fourth-Quarter 2016 Reported Diluted EPS(1) of $0.13, Adjusted Diluted EPS(2) of $0.47
- Provides 2017 Financial Guidance, Including Revenues of $52.0 to $54.0 Billion and Adjusted Diluted EPS(2) of $2.50 to $2.60; Reflects Pending Disposition of Hospira Infusion Systems, which Contributed $1.2 Billion of Revenues and $0.03 of Adjusted Diluted EPS(2) in 2016